EP Winer

1.8k total citations
40 papers, 530 citations indexed

About

EP Winer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, EP Winer has authored 40 papers receiving a total of 530 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 15 papers in Cancer Research. Recurrent topics in EP Winer's work include Advanced Breast Cancer Therapies (19 papers), Cancer Treatment and Pharmacology (13 papers) and Breast Cancer Treatment Studies (13 papers). EP Winer is often cited by papers focused on Advanced Breast Cancer Therapies (19 papers), Cancer Treatment and Pharmacology (13 papers) and Breast Cancer Treatment Studies (13 papers). EP Winer collaborates with scholars based in United States, Japan and France. EP Winer's co-authors include Wendy Demark‐Wahnefried, Vera Hárs, Kathleen A. Havlin, AH Partridge, Shari Gelber, R. Rosenberg, Clifford A. Hudis, C. Cirrincione, LA Carey and Hyman B. Muss and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Clinical Nutrition and Cancer Research.

In The Last Decade

EP Winer

39 papers receiving 510 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
EP Winer United States	10	443	208	115	91	59	40	530
Sebastian Lundgren Sweden	10	389 0.9×	94 0.5×	104 0.9×	37 0.4×	82 1.4×	21	541
Michaela Onstad United States	10	304 0.7×	177 0.9×	50 0.4×	42 0.5×	83 1.4×	24	736
C. Seynaeve Netherlands	16	299 0.7×	168 0.8×	163 1.4×	40 0.4×	210 3.6×	37	668
Lorraine Durcan United Kingdom	9	310 0.7×	281 1.4×	83 0.7×	30 0.3×	121 2.1×	10	454
Lorenzo Rossi Switzerland	10	192 0.4×	99 0.5×	110 1.0×	25 0.3×	33 0.6×	30	402
Yolanda Jerez Spain	12	297 0.7×	105 0.5×	83 0.7×	24 0.3×	53 0.9×	30	433
Domen Ribnikar Canada	11	291 0.7×	199 1.0×	151 1.3×	25 0.3×	104 1.8×	31	470
Shan Zheng China	13	271 0.6×	133 0.6×	103 0.9×	40 0.4×	48 0.8×	41	482
JN Atkins United States	11	303 0.7×	143 0.7×	200 1.7×	24 0.3×	50 0.8×	22	500
Valeria Forestieri Italy	10	387 0.9×	245 1.2×	101 0.9×	20 0.2×	78 1.3×	24	536

Countries citing papers authored by EP Winer

Since Specialization

Citations

This map shows the geographic impact of EP Winer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by EP Winer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites EP Winer more than expected).

Fields of papers citing papers by EP Winer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by EP Winer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by EP Winer. The network helps show where EP Winer may publish in the future.

Co-authorship network of co-authors of EP Winer

This figure shows the co-authorship network connecting the top 25 collaborators of EP Winer. A scholar is included among the top collaborators of EP Winer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with EP Winer. EP Winer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vaz-Luís, Inês, Graziella Mazza, Angela DeMichele, et al.. (2025). 485MO Health-related quality of life (HRQoL) from the PATINA trial (AFT-38): Impact of adding palbociclib to HER2 and endocrine therapy (ET) after induction in HR+/HER2+ metastatic breast cancer (MBC). Annals of Oncology. 36. S378–S378. 1 indexed citations

Metzger, Otto, Chiara Lambertini, IE Krop, et al.. (2021). 42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC). Annals of Oncology. 32. S37–S38. 3 indexed citations

Iwata, Hitoshi, Leisha A. Emens, Sylvia Adams, et al.. (2020). 49MO IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Annals of Oncology. 31. S1261–S1262. 8 indexed citations

Emens, Leisha A., Luciana Molinero, Sylvia Adams, et al.. (2020). 296P Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial. Annals of Oncology. 31. S360–S361. 23 indexed citations

Ligibel, JA, HS Rugo, HJ Burstein, et al.. (2018). Abstract P1-07-04: Physical activity, weight and outcomes in patients receiving first-line chemotherapy for metastatic breast cancer: Results from CALGB 40502 (Alliance). Cancer Research. 78(4_Supplement). P1–7. 1 indexed citations

Winer, EP, et al.. (2018). Abstract P4-10-04: EMBRACE (Ending metastatic breast cancer for everyone): A comprehensive approach to improve the care of patients with metastatic breast cancer. Cancer Research. 78(4_Supplement). P4–10. 1 indexed citations

Adams, Sylvia, Sherene Loi, D. Toppmeyer, et al.. (2018). Abstract PD6-10: KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1–positive, previously untreated, metastatic triple-negative breast cancer (mTNBC). Cancer Research. 78(4_Supplement). PD6–10. 22 indexed citations

Tanioka, Maki, Chuanwen Fan, LA Carey, et al.. (2017). Abstract S3-05: Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer. Cancer Research. 77(4_Supplement). S3–5. 1 indexed citations

Ligibel, JA, Melinda L. Irwin, Deborah Dillon, et al.. (2017). Abstract S5-05: Impact of pre-operative exercise on breast cancer gene expression. Cancer Research. 77(4_Supplement). S5–5. 3 indexed citations

10.

Ligibel, JA, Anita Giobbie‐Hurder, Laura Shockro, et al.. (2017). Abstract P5-11-02: Impact of pre-operative exercise and mind-body interventions on patient-reported outcomes in women with newly diagnosed breast cancer. Cancer Research. 77(4_Supplement). P5–11. 2 indexed citations

11.

Berry, DA, Bhupender Singh, C. Cirrincione, et al.. (2016). Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance). Cancer Research. 76(4_Supplement). S2–5. 51 indexed citations

12.

Tolaney, SM, DA Yardley, Beverly Moy, et al.. (2013). Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). Cancer Research. 73(24_Supplement). S1–4. 22 indexed citations

13.

Berry, DA, Bhupender Singh, Constance Cirrincione, et al.. (2013). Abstract S5-01: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). Cancer Research. 73(24_Supplement). S5–1. 39 indexed citations

14.

Isakoff, SJ, Tiffany A. Traina, LA Carey, et al.. (2012). Abstract PD09-03: Impact of BRCA1/2 Mutation Status in TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple negative breast cancer.. Cancer Research. 72(24_Supplement). PD09–3. 5 indexed citations

15.

Collins, LC, Shari Gelber, Sandra Kereakoglow, et al.. (2011). P4-11-12: Molecular Phenotype of Breast Cancers in a Large Cohort of Young Women According to Time Interval Since Pregnancy.. Cancer Research. 71(24_Supplement). P4–11. 12 indexed citations

16.

Krop, IE, Antonio C. Wolff, EP Winer, et al.. (2010). Abstract P6-15-02: A Phase Ib Study Evaluating Safety, Tolerability, Pharmacokinetics (PK), and Activity of the Phosphoinositide-3 Kinase (PI3K) Inhibitor GDC-0941 in Combination with Trastuzumab-MCC-DM1 (T-DM1) in Patients with Advanced HER2-Positive Breast Cancer. Cancer Research. 70(24_Supplement). P6–15. 8 indexed citations

17.

Ligibel, JA, et al.. (2010). Abstract S2-6: Aromatase Inhibitors and Risk of Myocardial Infarction, Stroke and Fracture. Cancer Research. 70(24_Supplement). S2–6. 2 indexed citations

18.

Gelber, Shari, et al.. (2006). Menopausal-type symptoms in young breast cancer survivors. Annals of Oncology. 17(12). 1777–1782. 72 indexed citations

19.

Harris, Lyndsay N., Charles M. Perou, Zoltán Szállási, et al.. (2005). Microarray profiling is feasible using archived tissue from a Cooperative Group Clinical Trial: Results from a pilot study in CALGB 9342. Journal of Clinical Oncology. 23(16_suppl). 545–545. 1 indexed citations

20.

Demark‐Wahnefried, Wendy, et al.. (1997). Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy. American Journal of Clinical Nutrition. 65(5). 1495–1501. 160 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact